← Leaderboards
Timothy L Lash
Emory University
$9,334,509
Attributed
$10,743,491
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.2K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,743,491 · 12
By mechanism
R01$8,950,795 · 5
P30$825,352 · 2
K07$434,970 · 1
R21$328,160 · 1
G13$159,594 · 1
R13$44,620 · 2
Top collaborators
- Kevin C Ward6 shared
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelProgramsCancer PatientMalignant NeoplasmsAffectInnovationCancer RecurrenceRecurrencePublic HealthPublic Health SchoolsMemberLeadershipQuality Of CareEvaluationMalignant Breast NeoplasmCancer SurvivorBiological MarkersUniversitiesPublishingCancer CareDiagnosisCenters For Disease Control And Prevention (U.S.)Cancer RiskResources
Grant awards (44)
Improving measurement of cancer registry completeness$594,400
R01 · FY2025 · CA · contact PI
Cancer Prevention and Control Research Program$258,889
P30 · FY2025 · CA · contact PI
Improving measurement of cancer registry completeness$653,500
R01 · FY2024 · CA · contact PI
Cancer Prevention and Control Research Program$55,733
P30 · FY2024 · CA · contact PI
Registering Cancer Recurrences in the Georgia Cancer Registry$26,979
R01 · FY2024 · CA
Registering Cancer Recurrences in the Georgia Cancer Registry$635,548
R01 · FY2023 · CA
Cancer Prevention and Control Research Program$54,381
P30 · FY2023 · CA · contact PI
Registering Cancer Recurrences in the Georgia Cancer Registry$631,169
R01 · FY2022 · CA
Improving Reproducibility by Incorporating Uncertainty$270,507
R01 · FY2022 · LM · contact PI
Cancer Prevention and Control$57,188
P30 · FY2022 · CA · contact PI
Registering Cancer Recurrences in the Georgia Cancer Registry$639,928
R01 · FY2021 · CA
Improving Reproducibility by Incorporating Uncertainty$270,527
R01 · FY2021 · LM · contact PI
Cancer Prevention and Control$82,644
P30 · FY2021 · CA · contact PI
Improving Reproducibility by Incorporating Uncertainty$270,544
R01 · FY2020 · LM · contact PI
Registering Cancer Recurrences in the Georgia Cancer Registry$268,597
R01 · FY2020 · CA
Cancer Prevention and Control$82,644
P30 · FY2020 · CA · contact PI
Registering Cancer Recurrences in the Georgia Cancer Registry$615,744
R01 · FY2019 · CA
Improving Reproducibility by Incorporating Uncertainty$295,837
R01 · FY2019 · LM · contact PI
Cancer Prevention and Control$82,644
P30 · FY2019 · CA · contact PI
Cancer Prevention and Control$82,644
P30 · FY2018 · CA · contact PI
Cancer Prevention and Control$13,364
P30 · FY2018 · CA · contact PI
Cancer Prevention and Control$4,861
P30 · FY2018 · CA · contact PI
New and integrated perspectives on modification of tamoxifen effectiveness$532,870
R01 · FY2017 · CA · contact PI
Cancer Prevention and Control$50,360
P30 · FY2017 · CA · contact PI
New and integrated perspectives on modification of tamoxifen effectiveness$552,166
R01 · FY2016 · CA · contact PI
Doctoral Student Workshop Co-Sponsored by the Society for Epidemiologic Research$22,310
R13 · FY2016 · CA · contact PI
New and integrated perspectives on modification of tamoxifen effectiveness$536,872
R01 · FY2015 · CA · contact PI
Does stanniocalcin predict late breast cancer recurrence, or is it a fish story?$140,115
R21 · FY2015 · CA · contact PI
New and integrated perspectives on modification of tamoxifen effectiveness$98,940
R01 · FY2015 · CA · contact PI
Doctoral Student Workshop Co-Sponsored by the Society for Epidemiologic Research$22,310
R13 · FY2015 · CA · contact PI
New and integrated perspectives on modification of tamoxifen effectiveness$514,141
R01 · FY2014 · CA · contact PI
Does stanniocalcin predict late breast cancer recurrence, or is it a fish story?$188,045
R21 · FY2014 · CA · contact PI
New and integrated perspectives on modification of tamoxifen effectiveness$579,942
R01 · FY2013 · CA · contact PI
Modification of tamoxifen effectiveness by gene polymorphisms and other drugs$234,985
R01 · FY2009 · CA · contact PI
Modification of tamoxifen effectiveness by gene polymorphisms and other drugs$234,985
R01 · FY2008 · CA · contact PI
Modification of tamoxifen effectiveness by gene polymorphisms and other drugs$234,985
R01 · FY2007 · CA · contact PI
Sensitivity analysis applied to epidemiology$80,695
G13 · FY2007 · LM · contact PI
Modification of tamoxifen effectiveness by gene polymorphisms and other drugs$257,629
R01 · FY2006 · CA · contact PI
Sensitivity analysis applied to epidemiology$78,899
G13 · FY2006 · LM · contact PI
SMOKING &GENETIC INTERACTION IN BREAST CANCER ETIOLOGY$54,705
K07 · FY2004 · CA
SMOKING &GENETIC INTERACTION IN BREAST CANCER ETIOLOGY$112,611
K07 · FY2003 · CA
SMOKING &GENETIC INTERACTION IN BREAST CANCER ETIOLOGY$54,707
K07 · FY2002 · CA
SMOKING &GENETIC INTERACTION IN BREAST CANCER ETIOLOGY$108,006
K07 · FY2001 · CA
SMOKING &GENETIC INTERACTION IN BREAST CANCER ETIOLOGY$104,941
K07 · FY2000 · CA